Program
deucravacitinib
Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.
Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 5912 open or running | phase 4since Jul 27, 2022 | Oct 3, 2016 | Nov 18, 2026phase 3 · NCT05946941 |
| AbbVie | 10 open or running | phase 4since Mar 21, 2024 | Mar 21, 2024 | none ahead |
Also a collaborator on its studies: covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Oct 3, 2016.
- Sep 23, 2022Phase 2 study in Alopecia AreataBristol-Myers Squibb · NCT05556265 · 94 enrolled · United States, Australia, Canada and more
- Nov 8, 20222 phase 3 studies in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT05617677, NCT05620407
- Jan 16, 2023Phase 4 study in PsoriasisBristol-Myers Squibb · NCT05701995 · 180 enrolled · United States, Puerto Rico
- Jul 7, 2023Phase 3 study in Sjogren's SyndromeBristol-Myers Squibb · NCT05946941 · 774 enrolled · United States, Argentina, Australia and more
- Sep 12, 2023Phase 4 study in Palmoplantar PsoriasisBristol-Myers Squibb · NCT06042920 · 130 enrolled · United States, Argentina, Canada
- Mar 21, 2024AbbVie's first study: phase 4 study in Moderate Plaque PsoriasisNew to AbbVieAbbVie · NCT06333860 · 393 enrolled · United States, Australia, Belgium and more
- Jun 21, 2024Phase 4 study in Healthy VolunteersBristol-Myers Squibb · NCT06476834 · 8 enrolled · United States
- Aug 21, 2024Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT06566768 · 52 enrolled · United Kingdom
- Jan 22, 2025Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT06851871 · 26 enrolled · United States
- Mar 6, 2025Phase 3 study in Arthritis, JuvenileBristol-Myers Squibb · NCT06869551 · 60 planned · United States, Brazil, Bulgaria and more
- Mar 12, 2025Phase 4 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT06875960 · 35 planned · United States
- May 13, 2025Phase 3 study in PsoriasisBristol-Myers Squibb · NCT06979453 · 366 planned · United States, Argentina, Belgium and more
- Aug 4, 2025Phase 3 study in Plaque PsoriasisBristol-Myers Squibb · NCT07116967 · 3,040 planned · United States, Argentina, Australia and more
- Aug 25, 2026Phase 3 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT07791199 · 2,300 planned
Ahead
- Nov 18, 2026Primary completion: phase 3 study in Sjogren's SyndromeBristol-Myers Squibb · NCT05946941
- Jan 31, 2028Primary completion: phase 4 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT06875960
- Jan 1, 2029Primary completion: phase 3 study in PsoriasisBristol-Myers Squibb · NCT04772079
- Oct 12, 2029Primary completion: phase 3 study in PsoriasisBristol-Myers Squibb · NCT06979453
TargetBeta
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
All 60 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07791199Lupus Erythematosus, Systemic | 3 | Not yet recruiting | Bristol-Myers Squibb | Oct 31, 2030 | 2,300 |
| NCT07116967Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 16, 2031 | 3,040 |
| NCT06979453Psoriasis · United States, Argentina, Belgium and more | 3 | Recruiting | Bristol-Myers Squibb | Oct 12, 2029 | 366 |
| NCT06875960Lupus Erythematosus, Systemic · United States | 4 | Recruiting | Bristol-Myers Squibb | Jan 31, 2028 | 35 |
| NCT06869551Arthritis, Juvenile · United States, Brazil, Bulgaria and more | 3 | Recruiting | Bristol-Myers Squibb | Mar 6, 2030 | 60 |
| NCT06851871Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Apr 4, 2025 | 26 |
| NCT06566768Healthy Participants · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jun 13, 2025 | 52 |
| NCT06476834Healthy Volunteers · United States | 4 | Completed | Bristol-Myers Squibb | Nov 2, 2024 | 8 |
| NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more | 4 | Completed | AbbVie | Mar 19, 2026 | 393 |
| NCT06042920Palmoplantar Psoriasis · United States, Argentina, Canada | 4 | Terminated | Bristol-Myers Squibb | Apr 25, 2025 | 130 |
| NCT05946941Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Nov 18, 2026 | 774 |
| NCT05701995Psoriasis · United States, Puerto Rico | 4 | Completed | Bristol-Myers Squibb | Aug 23, 2024 | 180 |
| NCT05620407Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Oct 19, 2026 | 513 |
| NCT05617677Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Oct 19, 2026 | 516 |
| NCT05556265Alopecia Areata · United States, Australia, Canada and more | 2 | Terminated | Bristol-Myers Squibb | Jan 6, 2024 | 94 |
| NCT05478499Psoriasis · United States, France, Germany and more | 4 | Completed | Bristol-Myers Squibb | Jan 11, 2024 | 154 |
| NCT04949269Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Jan 3, 2022 | 61 |
| NCT04908202Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Oct 10, 2024 | 670 |
| NCT04908189Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Nov 7, 2024 | 729 |
| NCT04877990Crohn Disease · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | Aug 29, 2023 | 67 |
| NCT04857034Lupus Erythematosus, Discoid · United States, Argentina, Australia and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Aug 22, 2024 | 74 |
| NCT04772079Psoriasis · Argentina, Australia, Brazil and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 1, 2029 | 153 |
| NCT04671953Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Mar 3, 2021 | 36 |
| NCT04613518Colitis, Ulcerative · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | May 31, 2023 | 38 |
| NCT04536961Healthy Volunteers · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Dec 25, 2020 | 56 |
| NCT04305899Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 25, 2020 | 40 |
| NCT04249284Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Mar 15, 2020 | 18 |
| NCT04209699Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Feb 4, 2020 | 18 |
| NCT04167462Psoriasis · China, Korea, Republic of, Taiwan | 3 | Completed | Bristol-Myers Squibb | Mar 8, 2021 | 220 |
| NCT04113668Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 19, 2019 | 48 |
| NCT04086719Healthy Male Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Oct 29, 2019 | 16 |
| NCT04065932Lupus · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Dec 8, 2019 | 33 |
| NCT04055506Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Sep 21, 2019 | 16 |
| NCT04036435Psoriasis · United States, Australia, Canada and more | 3 | Completed | Bristol-Myers Squibb | Jul 21, 2026 | 1,466 |
| NCT03979248Healthy · Netherlands | 1 | Completed | Bristol-Myers Squibb | Jul 7, 2019 | 21 |
| NCT03956953Autoimmune Diseases · China | 1 | Completed | Bristol-Myers Squibb | Sep 25, 2019 | 135 |
| NCT03934216Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Jun 13, 2021 | 131 |
| NCT03943147Lupus Nephritis · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Oct 29, 2020 | 16 |
| NCT03930602Healthy · United States | 1 | Completed | Bristol-Myers Squibb | May 27, 2019 | 16 |
| NCT03924427Psoriasis · Japan | 3 | Completed | Bristol-Myers Squibb | Mar 24, 2021 | 74 |
| NCT03920267Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Completed | Bristol-Myers Squibb | Mar 21, 2025 | 261 |
| NCT03890809Liver Diseases · Czechia, Hungary, Slovakia | 1 | Completed | Bristol-Myers Squibb | Nov 30, 2019 | 32 |
| NCT03890770Renal Insufficiency · United States, Czechia, Hungary and more | 1 | Completed | Bristol-Myers Squibb | Feb 7, 2020 | 44 |
| NCT03881059Active Psoriatic Arthritis · United States, Czechia, Germany and more | 2 | Completed | Bristol-Myers Squibb | Apr 27, 2020 | 203 |
| NCT03873415Psoriasis · United States | 1 | Completed | Bristol-Myers Squibb | May 1, 2019 | 9 |
| NCT03739788Healthy Participants · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Feb 11, 2019 | 8 |
| NCT03751228Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 26, 2018 | 9 |
| NCT03660436Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Oct 10, 2018 | 131 |
| NCT03624127Psoriasis · United States, Canada, China and more | 3 | Completed | Bristol-Myers Squibb | Sep 2, 2020 | 666 |
| NCT03611751Psoriasis · United States, Australia, Canada and more | 3 | Completed | Bristol-Myers Squibb | Nov 29, 2020 | 1,020 |
| NCT03599622Crohn Disease · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Dec 12, 2022 | 239 |
| NCT03541564Lupus Erythematosus, Systemic · United States | 1 | Completed | Bristol-Myers Squibb | Sep 4, 2018 | 84 |
| NCT03419910Psoriasis · United States | 1 | Completed | Bristol-Myers Squibb | May 4, 2018 | 54 |
| NCT03402087Arthritis, Psoriatic · Netherlands | 1 | Completed | Bristol-Myers Squibb | Mar 20, 2018 | 30 |
| NCT03262727Lupus Erythematosus, Systemic · United States | 1 | Completed | Bristol-Myers Squibb | Nov 23, 2017 | 49 |
| NCT03254784Lupus Erythematosus, Systemic · United States | 1 | Completed | Bristol-Myers Squibb | Nov 4, 2017 | 49 |
| NCT03252587Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Jun 29, 2021 | 363 |
| NCT03044873Autoimmune Diseases · United States | 1 | Completed | Bristol-Myers Squibb | Mar 14, 2017 | 20 |
| NCT03004768Psoriasis · United States | 1 | Completed | Bristol-Myers Squibb | Feb 27, 2017 | 6 |
| NCT02931838Psoriasis · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | Nov 16, 2017 | 268 |
How it is read
Names in the registry
- “BMS-986165”, 34 entries
- “Deucravacitinib”, 21 entries
- “BMS-986165 Tablet”, 2 entries
- “BMS-986165 Dose A”, 1 entry
- “BMS-986165 Dose B”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 16 studies
- Lupus Erythematosus, Systemic, 9 studies
- Arthritis, Psoriatic, 4 studies
- Crohn Disease, 2 studies
- Colitis, Ulcerative, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.